Reporting from AACR 2023, John V. Heymach discusses the EFS and pCR results from the AEGEAN trial testing neoadjuvant durvalumab plus platinum-based chemotherapy and followed after surgery with adjuvant durvalumab versus neoadjuvant placebo plus platinum-based chemotherapy in treatment-naïve patients with early stage resectable NSCLC. This is the first phase III trial to demonstrate the benefit of perioperative immunotherapy plus neoadjuvant chemotherapy in this setting.
Abstract: CT005 - AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC